慢性肾脏病诊断与检测进展
慢性肾脏病影响全球788–844百万成人,预计2040年成为第五大死因。检测进展包括用胱抑素C改进GFR估算、将白蛋白尿作为筛查与风险分层关键标志物,以及多组学、影像和人工智能推动无创诊断与精准医学。
要点
- 胱抑素C改进GFR估算,白蛋白尿用于筛查与风险分层。
- 多组学、影像和人工智能辅助无创诊断与病例发现。
- 基于eGFR和白蛋白尿的人群筛查策略成本效益渐佳。
核心结论
- 检测技术进步与筛查策略成本效益改善,但全球实施受可及性、验证和系统能力限制。
研究设计与样本
- 综述性文章,汇总慢性肾脏病诊断与检测进展,未报告原始研究样本量。
主要发现
- 全球成人慢性肾脏病患病人数为788–844百万,预计2040年成为第五大死因。
- 胱抑素C用于改进GFR估算,白蛋白尿被确认为筛查和风险分层关键标志物。
- 肾活检提高诊断准确性与预后预测,多组学推进疾病机制理解与精准医学前景。
- 先进影像与人工智能实现无创诊断和病例发现。
- 基于eGFR和白蛋白尿的人群筛查策略日益具有成本效益,尤其随着新疗法可及。
临床怎么用
- 可采用基于eGFR和白蛋白尿的筛查策略进行人群风险分层。
- 利用疾病特异性预测模型支持个体化风险分层与临床决策。
- 结合胱抑素C改进GFR估算,并重视白蛋白尿检测。
局限性
- 全球负担估计受 ascertainment bias 和检测可及性不足限制,尤其在中低收入国家。
- 可及性不平等、跨多样人群验证有限、生物标志物标准化缺口和卫生系统能力不足制约全球实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease affects 788-844 million adults worldwide and is projected to become the fifth leading cause of death by 2040. Global burden estimates remain limited by ascertainment bias and inadequate access to testing, particularly in low-income and middle-income countries. Advances in detection include improved estimation of glomerular filtration rate (GFR) using cystatin C and the recognition of albuminuria as a key marker for screening and risk stratification. Kidney biopsy is improving diagnostic accuracy and prognostic prediction, and multiomics approaches are advancing our understanding of disease mechanisms and hold promise for precision medicine. Advanced imaging and artificial intelligence are enabling non-invasive diagnostics and case detection. Population screening strategies using estimated GFR and albuminuria are increasingly cost-effective, particularly with the availability of novel therapies. Disease-specific prediction models support individualised risk stratification and clinical decision-making. However, inequitable access, limited validation across diverse populations, gaps in biomarker standardisation, and insufficient health-care system capacity constrain implementation globally. Addressing these challenges requires coordinated investment in diagnostics, workforce training, laboratory infrastructure, and health-care system strengthening alongside continued technological advancement.
引用
- Lees JS, Zhang L, Anandh U, et al. Advances in the diagnosis and detection of chronic kidney disease. Lancet. 2026. PMID: 42235558. doi:10.1016/S0140-6736(26)00702-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。